Qing Zhou,Dan Yang,Amanda K. Ombrello,Andrey V. Zavialov,Camilo Toro,Anton V. Zavialov,Deborah L. Stone,Jae Jin Chae,Sergio D. Rosenzweig,Kevin Bishop,Karyl S. Barron,Hye Sun Kuehn,Patrycja Hoffmann,Alejandra Negro,Wanxia L. Tsai,Edward W. Cowen,Wuhong Pei,Joshua D. Milner,Christopher Silvin,Theo Heller,David T. Chin,Nicholas J. Patronas,John S. Barber,Chyi-Chia R. Lee,Geryl M. Wood,Alexander Ling,Susan J. Kelly,David E. Kleiner,James C. Mullikin,Nancy J. Ganson,Heidi H. Kong,Sophie Hambleton,Fabio Candotti,Martha M. Quezado,Katherine R. Calvo,Hawwa Alao,Beverly K. Barham,Anne Jones,James F. Meschia,Bradford B. Worrall,Scott E. Kasner,Stephen S. Rich,Raphaela Goldbach-Mansky,Mario Abinun,Elizabeth Chalom,Alisa C. Gotte,Marilynn Punaro,Virginia Pascual,James W. Verbsky,Troy R. Torgerson,Nora G. Singer,Timothy R. Gershon,Seza Ozen,Omer Karadag,Thomas A. Fleisher,Elaine F. Remmers,Shawn M. Burgess,Susan L. Moir,Massimo Gadina,Raman Sood,Michael S. Hershfield,Manfred Boehm,Daniel L. Kastner,Ivona Aksentijevich

Abstract:BACKGROUND:We observed a syndrome of intermittent fevers, early-onset lacunar strokes and other neurovascular manifestations, livedoid rash, hepatosplenomegaly, and systemic vasculopathy in three unrelated patients. We suspected a genetic cause because the disorder presented in early childhood.METHODS:We performed whole-exome sequencing in the initial three patients and their unaffected parents and candidate-gene sequencing in three patients with a similar phenotype, as well as two young siblings with polyarteritis nodosa and one patient with small-vessel vasculitis. Enzyme assays, immunoblotting, immunohistochemical testing, flow cytometry, and cytokine profiling were performed on samples from the patients. To study protein function, we used morpholino-mediated knockdowns in zebrafish and short hairpin RNA knockdowns in U937 cells cultured with human dermal endothelial cells.RESULTS:All nine patients carried recessively inherited mutations in CECR1 (cat eye syndrome chromosome region, candidate 1), encoding adenosine deaminase 2 (ADA2), that were predicted to be deleterious; these mutations were rare or absent in healthy controls. Six patients were compound heterozygous for eight CECR1 mutations, whereas the three patients with polyarteritis nodosa or small-vessel vasculitis were homozygous for the p.Gly47Arg mutation. Patients had a marked reduction in the levels of ADA2 and ADA2-specific enzyme activity in the blood. Skin, liver, and brain biopsies revealed vasculopathic changes characterized by compromised endothelial integrity, endothelial cellular activation, and inflammation. Knockdown of a zebrafish ADA2 homologue caused intracranial hemorrhages and neutropenia - phenotypes that were prevented by coinjection with nonmutated (but not with mutated) human CECR1. Monocytes from patients induced damage in cocultured endothelial-cell layers.CONCLUSIONS:Loss-of-function mutations in CECR1 were associated with a spectrum of vascular and inflammatory phenotypes, ranging from early-onset recurrent stroke to systemic vasculopathy or vasculitis. (Funded by the National Institutes of Health Intramural Research Programs and others.).

ADA2 Deficiency (DADA2) As an Unrecognised Cause of Early Onset Polyarteritis Nodosa and Stroke: a Multicentre National Study

Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders

Clinical spectrum and outcome of children with deficiency of adenosine deaminase 2 (DADA2): multicentric experience from India

Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease with Severe Consequences

Early- Onset Stroke and Vasculopathy Associated with Mutations in Ada2

Case Report: Deficiency of Adenosine Deaminase 2 Presenting With Overlapping Features of Autoimmune Lymphoproliferative Syndrome and Bone Marrow Failure

Update on CECR1 Molecular Diagnostics: New Mutations in the Deficiency of ADA2 (DADA2) and the North American Polyarteritis Nodosa (PAN) Cohort

Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort

Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity

Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities

Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance

Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2)

Disrupted N-linked Glycosylation As a Disease Mechanism in Deficiency of ADA2.

Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India

A Narrative Review of the Neurological Manifestations of Human Adenosine Deaminase 2 Deficiency

A Cohort Study on Deficiency of ADA2 from China

Case Report: Susceptibility to viral infections and secondary hemophagocytic lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of adenosine deaminase 2 deficiency

Human ADA2 deficiency is characterized by the absence of an intracellular hypoglycosylated form of adenosine deaminase 2

Evaluation and Management of Deficiency of Adenosine Deaminase 2: an International Consensus Statement.

Clinical Follow-Up on a Cohort of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)

Two Unrelated Iranian Patients with Adenosine Deaminase 2 Deficiency: A Case Report and Review of Treatment